SPY
—
QQQ
707.87
−0.27%
BTC/USD
—
DIA
—
GLD
—
TLT
80.06
+0.01%
US
Sign in
Register
My Account
Benzinga
Markets & News
Markets
Stocks & Sectors
Stocks
Ratings & Research
Ratings
Trading
Trading
Screeners & Lists
Screeners
Learn
Learn
Premium
Premium Services
Markets & News
Breaking headlines, the trading day, and the calendars that move it.
Stocks & Sectors
Research any ticker, then drill into sectors, ratings, and options.
Ratings & Research
Wall Street calls, insider moves, and Benzinga's own stock rankings.
Trading
Options flow, trade calculators, and ideas for active traders.
Screeners & Lists
Filter the market your way, or start from a curated list.
Learn
Pick a broker, grow your savings, and protect what you've built.
Premium Services
Edge
Ratings, signals & screens
Pro
Real-time news & data terminal
Research
Trade alerts & newsletters
APIs
Market data licensing
All sections
DexCom Inc
DXCM
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$86.04
-1.67
-1.9%
Last update: Oct 16, 7:05 PM
$85.90
-1.81
-2.06%
Get Report
Overview
News
Earnings Forecast
Events
Price Targets
Financials
Sentiment
Ownership
Compare
Options
Stock Report
Privacy Manager
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga
Edge
Benzinga
Research
Benzinga
Pro
Logout
Earnings:
Q3 2026 Earnings in 11 days from now on Thu Oct 29th, after the market close
DexCom Financials
DexCom (DXCM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
DexCom Raises FY2026 Sales Guidance from $5.160B-$5.250B to $5.180B-$5.250B vs $5.224B Est
DexCom (NASDAQ:DXCM) raises FY2026 sales outlook from $5.160 billion-$5.250 billion to $5.180 billion-$5.250 billion vs $5.224 billion estimate.
Benzinga Newsdesk
PRO
DexCom Q2 Adj. EPS $0.70 Beats $0.61 Estimate, Sales $1.308B Beat $1.290B Estimate
DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.61 by 14.75 percent. This is a 45.83 percent increase over earnings of $0.48 per share from the same
Benzinga Newsdesk
Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
DexCom Sets 2030 Margin Targets, Projects Double-Digit Revenue Growth, Authorizes $1 Billion Share Buyback
Vandana Singh
PRO
DexCom Affirms FY2026 Sales Guidance of $5.160B-$5.250B vs $5.230B Est
2026 Annual GuidanceDexcom is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin, and reiterating guidance for Revenue and Non-GAAP Gross Profit Margin at the following
Benzinga Newsdesk
PRO
DexCom Q1 Adj. EPS $0.56 Beats $0.47 Estimate, Sales $1.191B Beat $1.175B Estimate
DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.47 by 19.15 percent. This is a 75 percent increase over earnings of $0.32 per share from the same period
Benzinga Newsdesk
Earnings Scheduled For April 30, 2026
Benzinga Insights
